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Kinins, a group of important pro-inflammatory peptides, 
are abundantly found in tissues and biological fluids of 
cancer patients. Bradykinin, the major representative 
of kinins, induces vascular permeability and, in conse-
quence, promotes tumor expansion. Additionally, the 
kinin-induced inflammatory responses, especially those 
mediated by kinin metabolites without the C-terminal 
arginine residue, lead to enhanced tumor growth. The 
present study aimed at analyzing the ability of the hu-
man glioblastoma cell line U-373, derived from a malig-
nant tumor, to produce kinin peptides. The proteins in-
volved in kinin generation, i.e., the kininogens and the 
kallikreins, were shown to be expressed in these cells. 
Moreover, tumor necrosis factor α, a proinflammatory 
cytokine that mediates tumorigenesis, was found to en-
hance the expression of enzymes associated with kinin 
production. The strong binding of kininogen to the cell 
surface and the enzymatic degradation of this protein by 
cells suggest the activation of kinin-generating systems. 
Indeed, glioblastoma cells, pre-treated with tumor necro-
sis factor α, released kinin peptides from exogenous kini-
nogen. The expression of kinin receptors in these cells 
was also shown to increase under the influence of this 
cytokine. Our results suggest that the human glioblas-
toma cell line U-373 constitutes a good cellular model 
that can be helpful in cancer research focused on kinin-
induced inflammation. Furthermore, our findings can 
contribute to new approaches in cancer treatment with 
the use of kinin receptor antagonists and inhibitors of 
kinin production.
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INTRODUCTION
Oncogenic transformation can be initiated and pro-
moted by inflammatory processes leading to tumor ap-
pearance and malignant progression (Finger & Giaccia, 
2010). Chronic inflammation and infections are central 
players in cancer. Besides, enhanced secretion of pro-
inflammatory mediators such as interleukins, interfer-
ons, tumor necrosis factor-α (TNF-α) and tumor growth 
factor-β results in increased angiogenesis, leukocyte re-
cruitment and cell proliferation (Geiger & Pepper, 2009; 
Lee et al., 2013). Moreover, some cytotoxic factors, such 
as proteases, cause cell detachment from the primary tu-
mor with subsequent malignant cell extravasation leading 
to the metastatic state (Geiger & Pepper, 2009).
The kinins, universal pro-inflammatory mediators, 
are also involved in cancer development. These pep-
tides were abundantly detected in tissues and biological 
fluids of cancer patients (Maeda et al., 1999). Bradykin-
in (BK), the major representative of this group, induces 
vascular permeability and, in consequence, promotes 
tumor expansion. Two primary kinins, BK and kallidin 
(KD) are produced by serine proteases, the kallikreins, 
from two precursor proteins, high molecular weight 
kininogen (HK) and low molecular weight kininogen 
(LK) (Bhoola et al., 1992; Colman & Schmaier, 1996; 
Blais et al., 2000). In tissues, KD is produced by the 
action of tissue kallikrein (hK1) on LK. In plasma, 
BK is formed from HK by plasma kallikrein within 
a multiprotein complex assembled on the surfaces of 
endothelium and blood cells via specific cell-membrane 
proteins (Joseph & Kaplan, 2005). This pathway of HK 
degradation and BK release is called the contact system 
activation. During the generation of kinins on the cell 
surfaces, some surface-bound proteases, such as factor 
XII or prolylcarboxypeptidase (PRCP) are involved in 
the activation of the plasma kallikrein zymogen, prekal-
likrein (PPK). Kinin concentration in extracellular fluids 
is controlled by specific peptidases, the kininases, that 
degrade kinins to shorter peptides (Bhoola et al., 1992; 
Blais et al., 2000). Most of kinin metabolites are bio-
logically inactive; however, some kininases of the car-
boxypeptidase class such as carboxypeptidase M (CPM) 
specifically remove only the C-terminal arginine residue 
of kinins, giving rise to strongly pro-inflammatory pep-
tides referred to as “des-Arg kinins”. The kinins and 
des-Arg kinins interact with two subtypes of cellular re-
ceptors, B1R and B2R, which belong to the G protein-
coupled receptor family. The full-length kinins are ago-
nists of B2R whereas des-Arg kinins bind specifically to 
B1R (Leeb-Lundberg et al., 2005). The kinin-mediated 
inflammatory responses, especially those induced by 
des-Arg kinins lead, to enhanced tumor growth (Leeb-
Lundberg et al., 2005). Recently, a novel approach 
based on the use of kinin receptor antagonists as anti-
cancer drugs has been suggested for cancer treatment 
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(Figueroa et al., 2012). Furthermore, a BK analog, Cere-
port, was introduced to increase the levels of chemo-
therapeutic agents in brain tumor and the surrounding 
tissue through the enhancement of permeability of the 
blood-brain tumor barrier (Dean et al., 1999). However, 
the authors emphasized the use of this B2R agonist as 
an adjunctive therapy. Increased permeability can also 
lead to cell migration and contributes to the invasion 
of glioblastoma, as has recently been shown by several 
research groups (Liu at al., 2010; López-Valdés et al., 
2010; Montana et al., 2011).
While the presence of kinin-like peptides in tumors 
is indisputable, the mechanisms of kinin production by 
tumor cells are poorly recognized. This study aimed at 
analyzing the ability of the human glioblastoma cell line 
U-373, derived from a malignant tumor, to produce 
kinins and des-Arg kinins from exogenous kininogens, 
especially after cytokine stimulation. In addition, the ef-
fect of TNF-α stimulation on the expression of kinin re-
ceptors by these cells was also determined.
MATERIALS AND METHODS
Chemicals. Des-Arg10-kallidin (DAKD), dansyl-
Ala-Arg-OH (DAA) and KD were supplied by Ba-
chem (Germany). TNF-α was obtained from BD Sci-
ences (Germany) and 2-mercaptomethyl-3-guanidinoe-
thyl thiopropanoic acid (MGTA) from Calbiochem 
(USA). Antibiotics, antimycotics, cell culture media, 
fetal bovine serum, non-essential amino acids and so-
dium pyruvate were purchased from Cytogen (Aus-
tria). HK was obtained from Enzyme Research Labo-
ratories (USA), captopril and 1,10-phenantroline from 
Fluka Analytical (Switzerland) and Fluorescein-Ex 
Protein Labeling kit from Molecular Probes (USA). 
[3H]-DAKD with a specific radioactivity of 88 Ci/
mmol and the Ultima GoldTM scintillation fluid were 
obtained from Perkin Elmer (USA). Bacitracin, Fast 
BCIP/NBT, tetracycline and other standard chemicals 
were purchased from Sigma (USA).
Mouse antihuman antibodies against a sequence en-
compassing amino acids 19-64 (within the HK heavy 
chain) and against a sequence encompassing amino acids 
438-531 (within the HK light chain) and goat antimouse 
IgG conjugate with alkaline phosphatase were supplied 
by Santa Cruz (USA).
Cell culture. The human glioblastoma cell line U-373 
supplied by ECACC (UK) was cultured in MEM me-
dium supplemented with non essential amino acids, 1 
mM sodium pyruvate, 10% fetal bovine serum, 1 U/ml 
penicillin, 0.1 mg/ml streptomycin and 2.5 μg/ml am-
photericin B in a humidified atmosphere containing 5% 
CO2 at 37°C.
The HEK-293 cell line with stably over-expressed 
mouse B1R was generated as described earlier (Zuba-
kova et al., 2007). Cells were cultured in high glucose 
DMEM medium supplemented with 10% fetal bovine 
serum and with an antibiotic/antimycotic mixture as 
described above. For binding experiments, cells were 
seeded in 96-well plates pre-treated with 0.01% solu-
tion of poly-lysine, and cultivated overnight to achieve 
80–100% confluence in culture medium. The cells were 
then treated with 10 μg/ml tetracycline in the medium 
for one day more to enrich the B1R expression at the 
cell surface.
Gene expression analysis. The total RNA of un-
treated cells or cells incubated with 10 ng/ml TNF-α 
for several hours was isolated with Total RNA Isola-
tion kit (Promega, USA). mRNA expression for B1R, 
B2R, CPM, hK1, kininogen, PPK, PRCP was analyzed 
with a two step RT-PCR procedure. The amount of 
elongation factor 2 (eEF2K) mRNA was also deter-
mined in each sample for the subsequent semiquantita-
tive analysis. After mRNA transcription with M-MLV-
Reverse Transcriptase kit (Promega, USA), amplifica-
tion of cDNA (2 μl) was performed in a 25 μl reaction 
mixture with the Taq polymerase kit (Finnzymes, Fin-
land), 0.1 mM dNTP (Fermentas, Canada) and 0.2 μM 
specific primers in a MJ Mini Personal Thermal cycler 
(BioRad Laboratories, USA). The primer pair sequences 
for the analyzed genes were obtained from Genomed 
(Poland) and are specified in Table 1. The anneal-
ing temperature for PCR reaction was 58°C, except 
for hK1 (68°C). The thermal cycler conditions were: 
95°C for 5 min, followed by 95°C for 30 s, 30 s at 
the corresponding annealing temperature, 72°C for 30 
s (35 cycles) and 10 min at 72°C. The PCR products 
for B1R, B2R, CPM, kininogen, hK1, PPK, PRCP and 
eEF-2K, resolved in 2% agarose gels, were 65 bp, 141 
bp, 715 bp, 233 bp, 151 bp, 141 bp, 160 bp, and 218 
bp long, respectively. For semiquantitative analysis, the 
gel-band intensity of the PCR products was measured 
by densitometry with the Fluor-S MultiImager (BioRad) 
and Quantity One software. The relative expression 
of genes was calculated as the ratio of the intensity of 
the analyzed PCR product band to the intensity of the 
eEF-2K PCR product band in each analyzed sample. 
The results are presented as the relative mRNA expres-
sion of the studied gene in response to TNF-α stimula-
tion. The relative mRNA expression in non-stimulated 
cells was assumed to equal 1.
Kininogen binding on cell surface. HK was la-
beled with fluorescein according to the manufacturer’s 
procedure. After dialysis and pro-
tein determination, the labeled 
kininogen (Fl-HK) was used for 
the cell binding study. Detached 
cells (0.5 × 106) were suspended in 
50 μl of solution of Fl-HK in Ty-
rode’s buffer supplemented with 
50 μM ZnCl2. The Fl-HK con-
centration ranged from 1.56 to 
150 nM. Control samples without 
the labeled kininogen were also 
prepared. After 1-h incubation, 
the cells were separated from un-
bound Fl-HK, gently washed with 
the binding buffer and the fluo-
rescence intensity of bound HK 
was analyzed with a Flow Cytom-
Table 1. Sequences of primers used for RT-PCR analysis.
Gene Forward primer Reverse primer
BR1 5’ gcccaagacaaacaccagatc 3’ 5’ gcaactgaacgtggcagaa 3’
BR2 5’ gtgcccatgccgcttgctcc 3’ 5’ tcggcgctgaaagaggccgt 3’
CPM 5’ gcctgatgatgatgtttttc 3’ 5’ tggtgatgtgggttgagttt 3’
eEF-2K 5’ gacatcaccaagggtgtgcag 3’ 5’ gcggtcagcacactggcata 3’
hK1 5’ gctcattgcatcagcgacaattacc 3’ 5’ ctgcttggcgggtgtggttct 3’
PPK 5’ tgggtaaccggatggggcttct 3’ 5’ agcacagaccatccgttgggtt 3’
Kininogen 5’ gcaagagtacaggtggtggctggca 3’ 5’ cctggaggccttttcatcagtgaga 3’
PRCP 5’ acaggtcctgggatgccattaatcg 3’ 5’ tagtccaccattgccagattcacc 3’
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eter LSRII (Becton Dickinson, USA) at lex = 488 
nm and lem = 530 nm.
Detection of kininogen degradation by Western 
blotting. Cells (3.0 × 106) were incubated with 10 ng/
ml TNF-α at 37°C for six hours in the culture me-
dium. After incubation, cells were washed and 100 
nM HK was added, followed by incubation for 1–2 
hours at 37°C. Then, the supernatants were separated 
from cells and prepared for electrophoretic analysis of 
HK degradation. Equal volumes of each sample (15 
μl) were subjected to SDS/PAGE (Laemmli system, 
10% gel), and the resolved polypeptides were trans-
ferred to polyvinylidene difluoride membranes (Sigma) 
in 10 mM CAPS buffer, pH 10.0 for 1 h. After an 
overnight blocking with 5% nonfat milk, the mem-
brane was incubated for 1 h at room temperature 
with mouse specific primary antibodies to human HK 
heavy and light chains at 1:1000 dilution. Next, after 
extensive washing, the membrane was incubated with 
the respective secondary antibody conjugated with al-
kaline phosphatase at 1:2000 dilution. After one hour 
incubation and extensive washing, the enzymatic reac-
tion with Fast BCIP/NBT was performed according 
to the manufacturer’s instructions.
Measurement of kinin and des-Arg kinin pro-
duction. Cells (3.0 × 106) were incubated with 10 ng/
ml TNF-α in MEM medium at 37°C for 6 h. After 
centrifugation, the supernatant was removed and the 
cells were incubated with 100 nM HK in 100 μl Ty-
rode’s buffer supplemented with 100 μM Zn2+, 100 
μM captopril and 500 μM bacitracin for up to 30 min 
at 37°C. After incubation, the samples were immedi-
ately placed in an ice bath and the supernatants were 
separated from cells by centrifugation, 5-fold diluted 
and immediately analyzed for kinin or des-Arg-kinin 
contents. Similar experiments, with the incubation of 
cells with 1 μM KD, were also performed. The kinins 
were determined with the Bradykinin EIA Kit (Penin-
sula, Germany) following the manufacturer’s instruc-
tions. The concentration of des-Arg kinins was meas-
ured using a competitive radiocompetitive receptor-
binding assay with B1R-overexpressing HEK-293 cells 
as previously described (Guevara-Lora et al., 2011).
Determination of carboxypeptidase activity. 
Analysis of the carboxypeptidase activity in U-373 
cells was performed by the measurement of enzymatic 
degradation of the labeled DAA peptide (Tan et al., 
1992). The procedure was optimized for the present 
study. For this purpose, 2 × 106 cells after 6-h incuba-
tion with 10 ng/ml TNF-α were lysed by a mild soni-
cation in PBS supplemented with protease inhibitor 
cocktail. Next, 50 μl of lysates were incubated with 
0.2 mM DAA in 0.1 M Hepes buffer, pH 7.0, supple-
mented with 0.2% Triton X-100 for 2 hours at 37°C. 
The enzymatic reaction was stopped by the addition 
of 150 μl of 1 M citric acid. The obtained product 
was extracted through the addition of 1 ml chloro-
form with vigorous vortexing. After centrifugation (10 
min, 1000 × g), the fluorescence of the organic phase 
was measured using a F-4500 fluorescence spectro-
photometer (Hitachi, Japan). Negative control samples 
(samples without cell lysate or samples with cell lysate 
but without DAA) as well as the samples in which the 
enzymatic activity was inhibited with 10 μΜ MGTA 
for 10 min before the incubation with substrate, were 
also prepared. The relative carboxypeptidase activity 
was presented as the difference of fluorescence in-
tensity between samples measured without or in the 
presence of 10 μM MGTA after 2-h incubation with 
substrate.
RESULTS AND DISSCUSION
Expression of the components of kinin-generating 
systems in glioblastoma cell line U-373
The abundance of kinin-generating proteins has been 
studied in diverse tissues confirming the presence of all 
the components necessary to produce these peptides in 
different types of cells (Blais et al., 2000; Fernando et al., 
2003; Joseph & Kaplan, 2005). The best studied system 
of cell surface-mediated kinin production is that of en-
dothelial cells but the activation of kinin-forming systems 
on other cells, including those involved in inflammatory 
processes was the subject of numerous studies (Barbasz 
& Kozik, 2009; Varano et al., 2011; Guevara-Lora et al., 
2011). The close relationship between inflammation and 
cancer has rationalized the investigation of the kinin 
role in processes associated with tumour formation and 
propagation (Maeda et al., 1999; Figueroa et al., 2012). 
In the current study, we analyzed the expression of the 
components of the kinin-generating system by the hu-
Figure 1. Expression of proteins involved in kinin generation in 
U-373 cells stimulated with TNF-α
Cells (3 × 106) were incubated with 10 ng/ml TNF-α at different 
time intervals (0.5, 1, 2, 4 and 6 hours) and the mRNA expression 
for hK1, PPK, PRCP, kininogen and eEF-2K was analyzed by two-
step RT-PCR. The obtained PCR products were separated in 2% 
agarose gel (A). Semi-quantitative analysis of RT-PCR was per-
formed by measuring the gel-band intensity of PCR products by 
densitometry. For each sample the intensity of the PCR product 
band at the time of maximal expression (6 h) was divided by the 
intensity of eEF-2K PCR product band and the ratio was compared 
to that of untreated cells assumed to equal 1 (B). The values rep-
resent means ± S.D. from at least three experiments.
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man glioblastoma cell line U-373, derived from a malig-
nant tumor. Our results demonstrated that enzymes in-
volved in the kinin generation, such as hK1, PPK and 
PRCP were present in cells at least at the mRNA level 
(Fig. 1). Moreover, expression of these enzymes could 
be induced by cytokines, such as TNF-α (Fig. 1). The 
relative expression for hK1, PPK and PRCP mRNA 
was considerably enhanced after 6-hour incubation with 
TNF-α. The expression of hK1 in our model cells was 
to be expected. The expression of tissue kallikreins in tu-
mors is unquestionable and some of these proteins are 
considered specific markers of carcinogenesis owing to 
their involvement in tumor metastasis and invasion (Bor-
gono et al., 2004, Obiezu & Diamandis, 2005; Chee et al., 
2008). A more interesting observation is the appearance 
of PPK expression in U-373 cells. In an earlier study, we 
demonstrated a minor expression of this kininogenase in 
neuroblastoma cell line IMR-32, suggesting a possibility 
of activation of the contact system by these cells (Gue-
vara-Lora et al., 2011). Like in that previous study, in the 
current work we also observed a slight increase in PPK 
expression in the presence of cytokines (by ca. 60%) 
(Fig. 1B). The probability that the contact system may 
be activated in U-373 cells is high, because these cells 
exhibited also a strong expression of PRCP that was ad-
ditionally enhanced by TNF-α (by 70%).
Despite the fact that expression of these enzymes 
was observed at the mRNA level, the results obtained 
from the incubation of exogenous HK with U-373 cells 
suggested their presence on the cell surface. Kinino-
Figure 2. Kininogen degradation by human glioblastoma cells
HK (100 nM) was incubated alone (lanes 1, 4) or with cells (3 × 106) 
without stimulation (lanes 2, 5) and after stimulation with 10 ng/
ml TNF-α (lanes 3, 6) for 1 h (lanes 1–3) or for 2 h (4–6). The ob-
tained products of HK degradation were selectively detected by 
Western blotting with specific antibodies against peptides with 
sequences belonging to the heavy and light chains of kininogen.
Figure 3. Binding of fluorescein-labeled HK to U-373 cells
Cells were incubated with Fl-HK at the concentration of up to 150 nM, for 1 h at 37°C. The percentage of cells with bound Fl-HK (A) and 
the mean fluorescence intensity from bound Fl-HK (B) were measured by flow cytometry. The results represent the mean ± S.D. from at 
least three experiments.
gen degradation after incubation with glioblastoma cells 
was studied by Western blotting with specific antibodies 
against HK chains (Fig. 2). Degradation of HK, visible 
already after 1-h incubation, was greater after one addi-
tional hour (lanes 2 and 5, respectively). Moreover, HK 
degradation was enhanced when cells were pre-treated 
with TNF-α (lanes 3 and 6, respectively). In each case, 
bands with molecular weights close to those expected for 
HK degradation by kallikreins were observed (Colman & 
Schmaier, 1997). However, the action of other proteinas-
es cannot be excluded because longer incubation of HK 
with cells led to extensive degradation with generation of 
protein bands with apparent molecular weights as low as 
about 35 kDa. Control samples containing HK without 
cells did not show protein degradation after 1- or 2-h 
incubation (lanes 1 and 4, respectively).
An important finding of the current work was the 
detection of kininogen mRNA in glioblastoma cell line 
U-373 (Fig. 1A). Although there were no evident chang-
es in the mRNA level after cytokine stimulation, these 
cells may be a source of kininogen production in nerv-
ous tissues, especially since a relatively high concentra-
tion of HK was reported in the cerebrospinal fluid (Sci-
cli et al., 1984).
Release of kinins and kinin-like peptides genered from 
exogenous kininogen by U-373 cells
Activation of the contact system requires kinino-
gen binding to the cell surface. We analyzed the bind-
ing of fluorescein-labeled HK to glioblastoma cells by 
flow cytometry. Representative plots for this interaction 
are shown in Fig. 3. The percentage of cells bearing the 
bound protein was comparable regardless of the num-
ber of cells incubated with Fl-HK (Fig. 3A). The plots 
of the fluorescence intensity of bound Fl-HK versus the 
total concentration of labeled kininogen added (the “sat-
uration binding” plots) are presented in Fig. 3B. These 
plots were numerically analyzed for the estimation of the 
apparent dissociation constant with the GraphPad Prism 
software. Although the saturation binding plots were dif-
ferent depending on the amount of cells taken for the 
analysis, the calculated dissociation constants were com-
parable, with a mean value of 9.2 ± 1.4 nM. These results 
are in agreement with an earlier study in which a strong 
HK binding at the surface of astrocytes was demonstrat-
ed (Fernando et al., 2003).
The demonstration of HK binding to cells allowed us 
to hypothesize that the contact system can be triggered 
on cell surface to release kinins, probably mainly BK. 
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Our study showed kinin generation from exogeneous 
HK by cells pre-treated with TNF-α. The incubation of 
cells with 100 nM HK resulted in a moderate produc-
tion of kinins which were measured using the EIA as-
say (Fig. 4A). A comparable concentration of kinins was 
observed after different incubation times, ranging from 1 
to 15 min (up to 1 nM). After 30 min, no kinins could 
be detected. The yield of kininogen degradation (rela-
tively to the total HK concentration added to cells) was 
low (about 1%). Nevertheless, since the kinin stationary 
levels result from a dynamic balance of kinin generation 
and degradation by peptidases (kininases), the presence 
of other peptides, such as des-Arg kinins should be con-
sidered.
Hence, simultaneously to the kinin concentration 
measurements, the generation of their metabolites, the 
des-Arg kinins, was also analyzed. To determine their 
concentration, a radioligand receptor-binding assay was 
applied. The production of des-Arg kinins reached a 
maximum after 5-min HK incubation with the cells (up 
to 2 nM) and slightly decreased with the increasing in-
cubation time (Fig. 4B). A higher concentration of these 
peptides as compared to that of full-length kinins in the 
same samples can be explained by different half-lives of 
both types of peptides (Blais et al, 2000). Different deg-
radation kinetics may lead to des-Arg kinin accumulation 
and promote chronic inflammatory processes. In tumor 
tissues, this fact may be of primordial importance ow-
ing to the pro-adhesive and chemotactic properties of 
these peptides (McLean et al., 2000; Guevara-Lora et al., 
2011). Leukocytes possess multiple roles in angiogenesis, 
as well as in tumor metastasis and invasion (Lee et al., 
2013). Therefore, the presence of des-Arg kinins may 
promote cancer through B1 receptors as has been sug-
gested recently (Molina et al., 2009).
The use of a potent inhibitor of carboxypeptidase ac-
tivity, MGTA, abolished the generation of des-Arg kinins 
from exogenous HK. The expression of CPM, the cell 
membrane-bound kininase responsible for the removal 
of the arginine residue from the kinin C-terminus, was 
analyzed by RT-PCR but no evidence of the expression 
of this enzyme at the mRNA level was observed (results 
not shown). Instead, determination of DAKD produc-
tion from exogenous KD using a radiocompetitive re-
ceptor-binding assay has shown a remarkable carboxy-
peptidase activity in glioblastoma U-373 cells (Fig. 5A). 
The cytokine pre-treated cells were able to degrade 1 μM 
KD quickly and effectively. After 5-min incubation with 
KD, the generated des-Arg kinin achieved the maximal 
concentration (up to 8 nM) that dropped by only 25% 
after 30 min. In the presence of 1 μM MGTA, the cells 
failed to generate DAKD. The ability of U-373 cells to 
remove C-terminal Arg residues was also tested by the 
measurements of 1 mM DAA degradation (Fig. 5B). 
The relative enzymatic activity of lysates obtained before 
and after TNF-α treatment for 3 hours demonstrated a 
Figure 4. Kinin and des-Arg kinin generation from exogenous HK by TNF-α-stimulated human glioblastoma cells
Cells (3.0 × 106) were stimulated with 10 ng/ml TNF-α for 6 hours. After stimulation, cells were incubated with 100 nM HK at 37°C for 1, 5, 
15 and 30 min, and the production of kinins (A) and des-Arg kinins (B) was determined by EIA and a radiocompetitive receptor-binding 
assay, respectively. The values represent means ± S.D. from at least three experiments.
Figure 5. Carboxypeptidase activity of the human glioblastoma cell line U-373
The production of des-Arg kinins by cells (3.0 × 106) pre-treated with 10 ng/ml TNF-α were determined after incubation with 1 μM KD 
at 37°C for 1, 5, 15 and 30 min. The des-Arg kinin concentration was measured by a radiocompetitive receptor-binding assay (A). The 
enzymatic activity of carboxypeptidases in untreated or TNF-α-stimulated cells was measured with 1 mM DAA for 2 hours. The relative 
enzymatic activity, calculated as the change of fluorescence intensity between samples incubated with 10 μM MGTA and untreated with 
the inhibitor was presented for non-stimulated or 10 ng/ml TNF-α stimulated cells (B). The values represent means ± S.D. from at least 
three experiments.
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high propensity of these cells to produce des-Arg kinins. 
An enhancement of carboxypeptidase activity was ob-
served with an increasing in cell number while TNF-α 
pretreatment did not significantly affect the enzymatic 
degradation of DAA. These results sufficiently support 
the hypothesis on the participation of carboxypeptidases 
in kinin degradation in the system studied. Although we 
failed to detect CPM mRNA in U-373 cells, other re-
searchers did confirm expression of this enzyme in the 
brain (Nagae et al., 1992). Moreover, it seems that other 
carboxypeptidases, such as carboxypeptidase E whose 
expression in glioblastoma cells was confirmed, can play 
a role in the formation of B1R agonists (Lynch et al., 
1990). Interestingly elevated expression of this carboxy-
peptidase correlates with tumor growth and metastasis in 
cancer (Murthy et al., 2010).
Expression of kinin receptors in glioblastoma cells after 
TNF-α stimulation
Given the above results, we examined the expression 
of kinin receptors in this cell model and the influence 
of TNF-α on this expression. The ratio of B1R or B2R 
mRNA expression to that of eEF-2K was calculated 
and the relative change in gene expression after TNF-α 
stimulation was estimed in comparision with untreated 
cells. Both B1R and B2R were expressed at mRNA lev-
el; however, B2R expression was higher as compared to 
B1R (Fig. 6). Our results are consistent with other stud-
ies in which both subtypes of kinin receptors in tumor 
tissues have been detected (Maeda et al., 1999; Wu et 
al., 2002; Molina et al., 2009; Toledo et al., 2012). The 
current finding that TNF-α influences kinin receptor ex-
pression is more original. Essential changes of kinin re-
ceptor expression after cytokine treatment were observed 
in the studied cellular model. The increase in B2R ex-
pression was moderate, with the maximal cytokine effect 
after 2 h incubation (40% increase) whereas B1R ex-
pression was much more strongly influenced by TNF-α 
(300% increase). In the case of B1R, TNF-α stimulated 
cells showed a fast (B1R expression increased by 60% 
already after 30-min incubation) and an extended (in-
creased expression was preserved up to 5 hours) effect. 
Such a difference in the expression of kinin re-
ceptors caused by pro-inflammatory cytokines 
may prove relevant to studies related to cancer 
treatment with antagonists that have gained in 
importance in recent years (Sharma & Al-Sherif, 
2011; Figueroa et al., 2012).
The results obtained in this work suggest that 
the selection of a cell model to study anticancer 
therapies is worth to be reconsidered. For exam-
ple, the new approaches in glioblastoma treat-
ment are associated with therapies which target 
the extracellular matrix and receptors, growth 
factors and cytokines, proteases, cytoskeletal 
components, oncogenes and tumor suppressor 
genes (Tysnes & Mahesparan, 2001). The elabo-
ration of appropriate and representative in vitro 
experimental systems is of pivotal importance 
for the characterization of processes involved 
in cancer cell invasion, especially at the molecu-
lar level. In our study we showed for the first 
time that tumor cells can produce kinins after 
cytokine stimulation. The kinins, in turn, can be 
converted into more stable peptides, the des-
Arg kinins, leading to an increase in the active 
peptide concentration in cancer tissues. Hence, 
this cell model offers new perspectives for anti-
cancer therapies and facilitates the search for 
new molecules that can be potential targets in therapies 
directed at inhibiting cell migration. Numerous studies 
have demonstrated that BR2 is a good candidate for anti-
cancer treatment (Jutras et al., 2010; Montana et al., 2011) 
but we suggest that B1R can be even a better target for 
anti-invasive therapy, because it is highly expressed in re-
sponse to inflammatory stimuli it. In a recent report, this 
receptor was shown to mediate glioma cell migration (Lu 
et al., 2010). Additionally, as suggested by our results, 
molecules involved in the production of kinin peptides, 
such as PRCP, kallikreins or carboxypeptidases can be 
promising candidates for the inhibition of cancer inva-
sion. The use of specific inhibitors of these enzymes can 
offer new perspectives on cancer treatment.
Concluding, in the current study we report the abil-
ity of kinin generation by cells derived from human glio-
blastoma. The probability that activation of the contact 
system is responsible for kinin release is high but the 
involvement of tissue kallikrein in this process cannot 
be excluded. These observations provide important data 
on the control of kinin effects in cancer tissues, which 
can be potentially useful for therapeutic purposes. In 
particular, our results suggest that not only the blocking 
of kinin receptors but also inhibition of the production 
of kinins and their des-Arg metabolites should be taken 
into consideration. Finally, the kinin effects can vary de-
pending on the stage of tumor development. We believe 
that the cellular model hereby analyzed can be useful for 
cancer treatment studies.
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